![]() |
|
|
Vol. 29, Issue 10, 1251-1255, October 2001
-Oxidation of Simvastatin in Mouse Liver
Preparations
Department of Drug Metabolism, All current 3-hydroxy-3-methylglutaryl-CoA reductase
inhibitors [simvastatin (SV), lovastatin (LV), atorvastatin,
pravastatin, fluvastatin, and cerivastatin] are believed to undergo an
atypical
Merck Research Laboratories,
West Point, Pennsylvania
-oxidation of the dihydroxy heptanoic or heptanoic acid
side chain. Metabolites, which are shortened by two- and/or four-carbon units consistent with
-oxidation products, have been reported exclusively in rodents following LV and SV administration and across
species (rodents, dogs, and humans) following the other statins. In
this study, in vitro formation of a
-oxidation product of
simvastatin hydroxy acid (SVA) and its intermediates in mouse livers is
described. Incubation of SVA with mouse liver preparations fortified
with CoASH and ATP led to formation of SV and two major products (P1
and P2). Based on mass spectrometry (MS), tandem mass spectrometry,
and/or NMR spectral characteristics, P1 was an
,
-unsaturated
metabolite, formed by dehydration of the
D,D-dihydroxy heptanoic acid side chain,
whereas P2 was probably the L,D-dihydroxy acid
isomer of SVA, formed by stereospecific hydration of P1. When
NAD+ was also included in the incubation mixture, there
were two additional metabolites with the MS and/or NMR characteristics
consistent with a two-carbon shortened product (P3) and its dehydrated
derivative (P4). In a complete incubation system with all cofactors
(ATP, CoASH, NAD+, and NADPH) present, there was an
additional product with MS spectra and liquid chromatography retention
time identical to the
-oxidized, unsubstituted pentanoic acid
metabolite (P5) detected in rats and mice following simvastatin
administration. The involvement of CoASH and NAD+ and the
presence of the four metabolic intermediates suggest that SVA (and
presumably the other statins) is a substrate for the
-oxidation
enzyme complex in mice. Additionally, the present finding of
CoASH-dependent formation of SV substantiates a mechanism proposed
previously for the in vivo lactonization of statin hydroxy acids.
This article has been cited by other articles:
![]() |
C. Li, R. Subramanian, S. Yu, and T. Prueksaritanont ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS Drug Metab. Dispos., January 1, 2006; 34(1): 102 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Clarke and L. A. Waskell The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin Drug Metab. Dispos., January 1, 2003; 31(1): 53 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, and J. H. Lin Effects of Fibrates on Metabolism of Statins in Human Hepatocytes Drug Metab. Dispos., November 1, 2002; 30(11): 1280 - 1287. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, J. H. Lin, P. G. Pearson, and T. A. Baillie Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization Drug Metab. Dispos., May 1, 2002; 30(5): 505 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Subramanian, X. Fang, and T. Prueksaritanont Structural Characterization of in Vivo Rat Glutathione Adducts and a Hydroxylated Metabolite of Simvastatin Hydroxy Acid Drug Metab. Dispos., March 1, 2002; 30(3): 225 - 230. [Abstract] [Full Text] [PDF] |
||||